ArticleJACC. Case reports2025
Live Hemodynamics-Assisted Simultaneous Aortic and Mitral Valve-in-Valve Replacement.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBioprosthetic valve failure is a growing challenge, particularly in high-risk patients who are poor surgical candidates. Simultaneous valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve replacement (TMVR) via a fully percutaneous approach remains a novel and evolving strategy with limited data. CASE SUMMARY: A 70-year-old man with failed aortic and mitral bioprostheses leading to severe intraprosthetic regurgitation presented with progressive heart failure symptoms. Owing to high surgical risk, he underwent transfemoral ViV-TAVR and transeptal ViV-TMVR using the SavvyWire for real-time hemodynamic monitoring and dedicated left ventricular pacing. The procedure was successful, with immediate hemodynamic improvement and no complications. DISCUSSION: This case demonstrates the feasibility, safety, and efficiency of simultaneous transfemoral ViV-TAVR and ViV-TMVR in high-risk patients with bioprosthetic valve failure. Although further data are needed, this case highlights a novel application of the SavvyWire, demonstrating its potential to enhance procedural precision, enable real-time hemodynamic assessment, and improve safety in simultaneous ViV-TAVR and ViV-TMVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.